Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
Clinical Pharmacology and Therapeutics|May 27, 2025
Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal ImpairmentNikki de Rouw, Leila-Sophie Otten, Mart P Kicken, et al.
The Lancet. Infectious Diseases|August 13, 2022
Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adultsSaskia C van der Boor, Merel J Smit, Stijn W van Beek, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 5, 2022
Efficacy of BCG Vaccination Against Respiratory Tract Infections in Older Adults During the Coronavirus Disease 2019 PandemicSimone J C F M Moorlag, Esther Taks, Thijs Ten Doesschate, et al.
Clinical Lung Cancer|April 22, 2025
The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort StudyMart P Kicken, Rob Ter Heine, Intissar Azarfane, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2026
Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumabYan Wang, Laura H Bukkems, Johan G C van Hasselt, et al.
The Lancet. Microbe|January 21, 2023
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2Merel J Smit, Adam F Sander, Maud B P A Ariaans, et al.
Frontiers in Oncology|March 27, 2023
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)Marinda Meertens, M Benthe Muntinghe-Wagenaar, Barend J Sikkema, et al.
Targeted Oncology|April 20, 2023
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung CancerRob Ter Heine, Michel M van den Heuvel, Berber Piet, et al.
Kidney International Reports|June 19, 2026
Atypical Hemolytic Uremic Syndrome in Children and Adults With the Hot Spot C3 Gene Variant p.Arg161TrpLieke Ter Steeg, Romy N Bouwmeester, Mendy Ter Avest, et al.
Kidney International Reports|January 16, 2023
Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS StudyRomy N Bouwmeester, Caroline Duineveld, Kioa L Wijnsma, et al.
Pageof 16